Galderma presents 3-year ARCADIA LTE data for Nemluvio in atopic dermatitis
Galderma presented three-year ARCADIA long-term extension study data showing sustained improvements with Nemluvio (nemolizumab) in patients with atopic dermatitis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Galderma presents three-year Nemluvio data at EADV 2026
Galderma said new ARCADIA extension data show sustained improvements with Nemluvio for up to three years in moderate-to-severe atopic dermatitis. The company also said no new safety signals were identified in the study.